Clinical trials: Residual Disease
Breast Cancer
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative…
- Trial name
- NCT07400523
- Testing
- Ribociclib plus aromatase inhibitor, Aromatase inhibitor
- Where
- 4 sites in China
- Volunteers
- 446 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Biliary Tract Cancer
ctDNA Detection of MRD in Predicting Postoperative Recurrence in Biliary Tract Cancers：A Multicenter Prospective Trial
A substantial proporation of patients with biliary tract malignancies still experience disease recurrence after curative resection.
- Trial name
- NCT05743959
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Leukemia, Chronic Lymphocytic Leukemia
Mosunetuzumab for CLL MRD Clearance
The goal of this study is to test mosunetuzumab given alone or in combination with a Bruton tyrosine kinase inhibitor (BTKi, such as ibrutinib, acalabrutinib, zanubrutinib, or pirtobrutinib) in participants with CLL (chronic…
- Conditions
- Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma
- Trial name
- NCT07052695
- Testing
- Mosunetuzumab, Ibrutinib, Acalabrutinib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Inhye Ahn
Acute Lymphoblastic Leukemia
Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
This investigator-initiated, prospective, single-arm, open-label, single-center clinical study aims to evaluate the efficacy and safety of Inaticabtagene autoleucel (Inati-cel;CNCT19)CD19 CAR-T theraphy in adults B-ALL that are…
- Trial name
- NCT06718244
- Testing
- single dose of Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ruijin Hospital
Malaria
RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission
Reactive treatment of household contacts of a confirmed malaria case has been shown to reduce infection prevalence since the former as they are at an increased risk of infection.
- Trial name
- RHOST (NCT02878200)
- Testing
- dihydroartemisinin-piperaquine
- Where
- The Gambia
- Volunteers
- 2,236 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Chronic Lymphocytic Leukemia
A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan
Most cases of Chronic lymphocytic leukemia (CLL) remain an incurable disease with the goal of therapy being to improve quality of life and to prolong survival.
- Trial name
- NCT06362044
- Where
- Japan
- Volunteers
- 89 people
- Sponsor
- AbbVie
Anemia
Milking the Umbilical Cord at Term Cesarean Birth
The purpose of this pilot study is to determine if umbilical cord milking at the time of scheduled cesarean section effects the hemoglobin and hematocrit levels of full-term infants as determined by hemoglobin and hematocrit…
- Trial name
- NCT01630993
- Testing
- Umbilical Cord Milking
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Lung Cancer, Nonsmall Cell
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
This study aims to incorporate circulating tumor DNA (ctDNA)-minimal residual disease (MRD) to personalize the administration of consolidation toripalimab therapy in resected stage IB-IIIA non-small-cell lung cancer (NSCLC) after…
- Trial name
- CONTINUE (NCT06426511)
- Testing
- Toripalimab+Chemotherapy, Toripalimab+Chemotherapy followed by consolidation toripalimab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Sun Yat-sen University
End-stage Renal Disease (ESRD)
NIRS for the Diagnosis of Residual Renal Function Injury in Hemodialysis Patients
Hemodialysis (HD) is the main renal replacement therapy for patients with end-stage renal disease (ESRD), accounting for approximately 69% of all renal replacement therapies and 89% of all dialysis.
- Trial name
- HDRRFI-NIRS (NCT06243900)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Yuanjun Yang
Acute Myeloid Leukemia (AML), FMS-like Tyrosine Kinase-3 (FLT3) Mutations
Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)
The purpose of this study is to provide expanded access to ASP2215 for subjects with FLT3-mutated relapsed or refractory AML or FLT3-mutated AML in composite complete remission (CRc) (complete remission [CR], complete remission…
- Trial name
- NCT03070093
- Testing
- gilteritinib
- Where
- 39 sites in United States, Canada and 1 more
- Sponsor
- Astellas Pharma Global Development, Inc.
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Breast Cancer, Triple Negative Breast Neoplasms
Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease
To evaluate the clinical benefit of a post-operative adjuvant therapy combining radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitabine in Triple Negative Breast Cancer (TNBC) patients with residual disease after…
- Trial name
- BreastImmune03 (NCT03818685)
- Testing
- Nivolumab, Ipilimumab, Capecitabine
- Where
- 17 sites in France
- Volunteers
- 95 people
- Sponsor
- Centre Leon Berard
Acute Myeloid Leukemia
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
The VERDI study is an investigator-initiated, multicenter, multicohort, phase II trial with combination of venetoclax + azacitidine for patients treated for AML under according to an intensive chemotherapy protocol (CETLAM-20)…
- Trial name
- VERDI (NCT06668558)
- Testing
- Azacitidine (AZA), Venetoclax
- Where
- 14 sites in Spain
- Volunteers
- 28 people
- Sponsor
- Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Pituitary Adenoma, Nonfunctioning Pituitary Adenoma
Cabergoline in Nonfunctioning Pituitary Adenomas
Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended.
- Trial name
- NCT03271918
- Testing
- Cabergoline
- Where
- Brazil
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Rectal Cancer
1. SAFE-AI ONCO-TRACK: Multimodal GenAI for Early Detection of Minimal Residual Disease and Recurrence in Gastrointestinal Oncology
Current decision tools (TNM, MRI/PET, CEA, and other serum markers, as well as single-marker genomics) are insufficiently predictive of responders, fail to detect early MRD in many cases, and rarely connect molecular biology to…
- Trial name
- ONCO-TRACK (NCT07189520)
- Testing
- Artificial Intelligence
- Volunteers
- 700 people
- Sponsor
- Università Politecnica delle Marche
Aggressive Periodontitis, Generalized
Comparison Between Surgical Access and Repeated Applications of APDT
The aim of this study will be to compare the approach of repeated applications of APDT versus surgical therapy for the treatment of residual pockets in generalized agressive periodontitis.
- Trial name
- NCT03140059
- Testing
- Open flap debridement, Repeated application of aPDT
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
Multiple Myeloma
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation.
- Trial name
- NCT03941860
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 222 sites in United States, Puerto Rico
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
Assessing Residual Inflammation and Macrophage Presence in Lupus Nephritis After 3 Months of Intensified Treatment With Prednisolone, Mycofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and Prednisolone
The goal of this clinical trial is to learn how different treatments affect immune cells in the kidney in people with active lupus nephritis (LN), a kidney manifestation of systemic lupus erythematosus (SLE).
- Trial name
- MAPLE (NCT07760480)
- Testing
- Kidney Biopsy, Voclosporin (LUPKYNIS), Blood, feces and urine sample collection
- Where
- Netherlands
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Stem Cell Transplant Complications, Leukemia, Myeloid, Acute
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure.
- Conditions
- Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
- Trial name
- NCT03793517
- Testing
- Decitabine, mBU/CY and ATG, mBU/CY
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia (ALL)
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
This is a phase II, open-label, nonrandomized, prospective study to evaluate the activity, safety, and feasibility of administration of moxetumomab pasudotox in the pre-allogeneic hematopoietic cell transplantation (HCT) setting…
- Trial name
- NCT02338050
- Testing
- Moxetumomab Pasudotox
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Center for International Blood and Marrow Transplant Research